Sarepta Therapeutics (SRPT) Non Operating Income (2010 - 2026)

Sarepta Therapeutics' Non Operating Income history runs 17 years deep, the most recent figure standing at -$15.3 million for Q1 2026.

• In Q1 2026, Non Operating Income rose 81.64% year-over-year to -$15.3 million; the TTM figure through Mar 2026 stood at $65.4 million (up 239.26% YoY), while the FY2025 annual figure was -$2.4 million, down 105.72% from the prior year.
• Non Operating Income for Q1 2026 stood at -$15.3 million, down from $133.3 million in the prior quarter.
• The five-year high for Non Operating Income was $133.3 million in Q4 2025, with the low at -$374.6 million in Q1 2023.
• The 5-year median for Non Operating Income is -$12.3 million (2023), against an average of -$29.8 million.
• The sharpest annual moves came in 2023 and 2025: Non Operating Income plunged 2069.83% in 2023, then surged 1224.66% in 2025.
• Sarepta Therapeutics' Non Operating Income stood at -$119.9 million in 2022, then jumped by 113.13% to $15.7 million in 2023, then plunged by 36.1% to $10.1 million in 2024, then soared by 1224.66% to $133.3 million in 2025, then slumped by 111.45% to -$15.3 million in 2026.
• Business Quant data shows SRPT's Non Operating Income at -$15.3 million in Q1 2026, $133.3 million in Q4 2025, and -$90.7 million in Q3 2025.